<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175159</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA042805-01A1</org_study_id>
    <nct_id>NCT03175159</nct_id>
  </id_info>
  <brief_title>Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse</brief_title>
  <official_title>Integrated Behavioral Activation and HIV Risk Reduction Counseling for Men Who Have Sex With Men (MSM) With Stimulant Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fenway Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks primarily to test, in a two-arm randomized controlled trial (RCT), the&#xD;
      efficacy of Project IMPACT, an intervention that integrates Behavioral Activation (BA) with&#xD;
      HIV risk reduction (RR) counseling for HIV-uninfected men who have sex with men (MSM) with&#xD;
      stimulant use disorder at risk for HIV via sexual behavior. HIV-uninfected MSM with a&#xD;
      diagnosis of stimulant use disorder will be equally randomized to one of two study arms: (1)&#xD;
      the Project IMPACT intervention, BA-RR counseling, which lasts ten sessions; and (2) the&#xD;
      standard of care (SOC) comparison condition, including two equivalent sexual risk-reduction&#xD;
      counseling sessions. Participants will be followed for one year post-randomization, with&#xD;
      assessments at months four, eight, and 12.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project IMPACT targets both stimulant use and sexual risk reduction in effort to help&#xD;
      individuals relearn how to enjoy safe but pleasurable activities. The intervention integrates&#xD;
      BA, an evidence-based cognitive behavior therapy for improving mood and increasing activity,&#xD;
      incorporated with RR counseling aimed to reduce risky sexual practices, and potential HIV&#xD;
      acquisition. This RCT is a two-arm efficacy trial, comparing the Project IMPACT Intervention&#xD;
      with a SOC arm. All participants will receive HIV testing, pre-/post-test risk reduction&#xD;
      counseling, oral swab toxicology test at baseline and 12 months, assessment of&#xD;
      interest/indication for Pre-Exposure Prophylaxis (PrEP) per Center for Disease Control&#xD;
      guidelines, and active referral to local PrEP services as standard-of-care. Finally, the RCT&#xD;
      will integrate resource utilization and cost-effectiveness analyses to examine cost&#xD;
      efficiency of the Project IMPACT Intervention as a component of data analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Two-arm RTC, equally randomized between two arms: (1) the Project IMPACT intervention, &quot;BA-RR&quot; (behavioral activation and HIV risk reduction) counseling, which lasts ten sessions; and (2) the standard of care comparison condition, including two equivalent sexual risk reduction counseling sessions.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcome assessor will not be aware of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Condomless Anal Sex Acts (CAS) over study follow-up</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>A self reported change in the number of CAS with men without protection of PrEP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in the number of stimulant use episodes over study follow-up</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>A self reported change in the number of stimulant use episodes over study follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Stimulant Abuse</condition>
  <condition>HIV Prevention</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sexual risk-reduction counseling sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavioral Activation &amp; Risk Reduction Counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioral activation with risk reduction counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>IMPACT</intervention_name>
    <description>Ten counseling sessions</description>
    <arm_group_label>Behavioral Activation &amp; Risk Reduction Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Two counseling sessions</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Assigned male at birth&#xD;
&#xD;
          -  HIV-uninfected verified via rapid HIV test&#xD;
&#xD;
          -  Self-reports in the past four months: CAS receptive or insertive with a cisgender male&#xD;
             sexual partner, while using stimulants and without the protection of Pre-Exposure&#xD;
             Prophylaxis (PrEP)*&#xD;
&#xD;
          -  Able to read, speak, and understand English&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not live in the greater Boston or Miami areas, or will move away from Boston or&#xD;
             Miami within the next 12 months&#xD;
&#xD;
          -  Self-reports being 100% adherent to PrEP in the last four months&#xD;
&#xD;
          -  Unable to provide informed consent due to severe mental or physical illness, or&#xD;
             substance intoxication at the time of interview&#xD;
&#xD;
          -  Discovery of active suicidal ideation at the time of interview (participants will be&#xD;
             referred immediately for treatment, but may join the study once resolved)-&#xD;
&#xD;
          -  Involvement in any other HIV Prevention study that may interfere with the ability to&#xD;
             test major study outcomes (e.g. another sexual risk reduction intervention or PrEP&#xD;
             adherence intervention)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Intervention addresses stimulant use and HIV risk reduction in MSM</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Mimiaga, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles, Fielding School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Safren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew J Mimiaga, ScD, MPH</last_name>
    <phone>617-901-9276</phone>
    <email>mmimiaga@ph.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve Safren, PhD</last_name>
    <phone>305 284-2814</phone>
    <email>ssafren@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331462926</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Safren, PhD</last_name>
      <phone>305-528-4281</phone>
      <phone_ext>14</phone_ext>
      <email>ssafren@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>022154302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Mayer, MD</last_name>
      <phone>617-927-6400</phone>
      <email>kmayer@fenwayhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Matthew Mimiaga, ScD, MPH, MA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Risk Reduction</keyword>
  <keyword>Crystal Methamphetamine</keyword>
  <keyword>Cocaine</keyword>
  <keyword>Stimulant Abuse</keyword>
  <keyword>HIV</keyword>
  <keyword>Behavioral Activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Raw data for additional analysis will be available to outside individuals through contacting the Multiple Principal Investigators (MPI) at two different times. The first will be after all of the baseline data is collected. We will institute a concept plan process where internal study staff first have the availability to write papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, we will welcome this collaboration. A similar process will happen for outcome data; however, this will not be possible until the publication and release of the outcome paper(s). The MPIs (Mimiaga and Safren) will store the data indefinitely and allow access for pooled data analysis projects, or projects for outside individuals. Information regarding the availability of data for analysis will be listed on the MPIs' program's web page. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.</ipd_description>
    <ipd_time_frame>The first time point at which outside investigators may request IPD will be after all of the baseline data has been collected and internal study staff have been offered the availability to write papers or give presentations on particular topics. A similar process will take place for outcome data following publication and release of the outcome paper(s). The MPIs (Mimiaga and Safren) will store the data indefinitely.</ipd_time_frame>
    <ipd_access_criteria>Raw data for additional analysis will be available to outside individuals through contacting the Multiple Principal Investigators (MPI). We will institute a concept plan process where internal study staff first have the availability to write papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, we will welcome this collaboration. The MPIs (Mimiaga and Safren) will store the data indefinitely and allow access for pooled data analysis projects, or projects for outside individuals. Information regarding the availability of data for analysis will be listed on the MPIs' program's web page.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 9, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03175159/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

